SCHEMBL887595

SCHEMBL887595

Cc1nc2cncnc2n1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 18/20 0.50
CYP3A4 P08684 14/20 0.50
TSHR P16473 7/20 0.50
CLK4 Q9HAZ1 4/20 0.50
HSD17B10 Q99714 9/20 0.48
USP2 O75604 9/20 0.48
CYP2C9 P11712 12/20 0.46
ALDH1A1 P00352 11/20 0.46
CYP2C19 P33261 8/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HIF1A Q16665 1/20 0.46
MAPK1 P28482 2/20 0.44
LMNA P02545 1/20 0.40
ALOX15 P16050 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CDK9 P50750 1/20 0.36
DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23346841 0.78 CYP1A2 (0.49) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL19055938 0.78 CYP1A2 (0.46) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL28194814 0.78 CYP1A2 (0.43) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL14879948 0.78 CYP1A2 (0.49) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL21927511 0.76 CDK5 (0.45) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL21925844 0.76 CYP1A2 (0.48) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL19428747 0.76 CYP1A2 (0.41) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL11916063 0.76 CYP1A2 (0.47) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL11946715 0.76 CYP1A2 (0.47) CYP1A2CYP3A4TSHRCLK4HSD17B10
SCHEMBL9690911 0.75 CYP1A2 (0.48) CYP1A2CYP3A4TSHRCLK4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3873484-B1 NOVEL STING AGONISTS VENENUM BIODESIGN LLC (US) 2023-08-23 EP disclosed
WO-2021110890-A1 PYRIDINIUM DERIVATIVES AS HERBICIDES SYNGENTA CROP PROTECTION AG (CH) 2021-06-10 WO disclosed
US-10760116-B2 Analysis kit, analyzer, and methods for analyzing template nucleic acid or target substance KABUSHIKI KAISHA DNAFORM (JP) 2020-09-01 US disclosed
EP-3339447-B1 METHOD FOR ANALYZING TEMPLATE NUCLEIC ACID, METHOD FOR ANALYZING TARGET SUBSTANCE, ANALYSIS KIT FOR TEMPLATE NUCLEIC ACID OR TARGET SUBSTANCE, AND ANALYZER FOR TEMPLATE NUCLEIC ACID OR TARGET SUBSTANCE DNAFORM KK (JP) 2020-07-29 EP disclosed
EP-3401407-B1 NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE DNAFORM KK (JP) 2020-04-22 EP disclosed
US-10428371-B2 Fluorescent labeled single-stranded nucleic acid and use thereof KABUSHIKI KAISHA DNAFORM (JP) 2019-10-01 US disclosed
US-20190032108-A1 METHOD FOR ANALYZING TEMPLATE NUCLEIC ACID, METHOD FOR ANALYZING TARGET SUBSTANCE, ANALYSIS KIT FOR TEMPLATE NUCLEIC ACID OR TARGET SUBSTANCE, AND ANALYZER FOR TEMPLATE NUCLEIC ACID OR TARGET SUBSTANCE RIKEN (JP) 2019-01-31 US disclosed
EP-2891714-B1 METHOD FOR ANALYZING TARGET NUCLEIC ACID, KIT, AND ANALYZER DNAFORM KK (JP) 2018-07-11 EP disclosed
EP-3339447-A1 METHOD FOR ANALYZING TEMPLATE NUCLEIC ACID, METHOD FOR ANALYZING TARGET MATERIAL, KIT FOR ANALYZING TEMPLATE NUCLEIC ACID OR TARGET MATERIAL, AND DEVICE FOR ANALYZING TEMPLATE NUCLEIC ACID OR TARGET MATERIAL Kabushiki Kaisha DNAFORM (JP) 2018-06-27 EP disclosed
US-9862989-B2 Nucleic acid probe, method for designing nucleic acid probe, and method for detecting target sequence KABUSHIKI KAISHA DNAFORM (JP) 2018-01-09 US disclosed
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 US disclosed
US-20080227104-A1 Replication; hybridization; kits RIKEN (JP) 2008-09-18 US disclosed
US-20080227104-A1 Replication; hybridization; kits RIKEN (JP) 2008-09-18 US disclosed
EP-1970453-A2 Primer, primer set, and nucleic acid amplification method and mutation detection method using the same Riken (JP) 2008-09-17 EP disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 US disclosed
US-20080167306-A1 Novel Heteroaryl Derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-10 US disclosed
US-20080167306-A1 Novel Heteroaryl Derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-10 US disclosed
US-20080119466-A1 Heteroarylphenylurea Derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-22 US disclosed
EP-1837329-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2007-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167306-A1 Novel Heteroaryl Derivative GPR119, SLC2A4, SLC5A2 CYP1A2 186/4885CYP3A4 252/4885TSHR 1325/4885
US-20080227104-A1 Replication; hybridization; kits PCNA, POLL, RNGTT CYP1A2 4851/4885CYP3A4 4220/4885TSHR 2406/4885
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE NR0B1, UGT1A10, NR0B2 CYP1A2 30/4885CYP3A4 21/4885TSHR 1748/4885
US-20080119466-A1 Heteroarylphenylurea Derivative CHRM1, CBR3, CHRM2 CYP1A2 15/4885CYP3A4 31/4885TSHR 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.